ORIC Pharmaceuticals Reports Q3 GAAP EPS of -$0.44, Missing Estimates by $0.05
ORIC Pharmaceuticals reported third-quarter financial results featuring a GAAP earnings per share (EPS) of -$0.44, which fell short of market expectations by $0.05. The miss highlights ongoing profitability challenges for the company as it continues its clinical and operational activities. Despite the earnings miss, the company maintains a significant liquidity position. As of September 30, 2026, ORIC reported total cash, cash equivalents, and investments amounting to $345.4 million. This capital includes $59.9 million in net proceeds generated through its at-the-market (ATM) program during the first quarter.

Tickers: $ORIC